Bio-Gene Raises $2.46M as Flavocide and Qcide Hit Key Milestones
Bio-Gene Technology Limited updates on its development of two novel insecticides, Flavocide and Qcide, highlighting regulatory progress, commercial partnerships, and a strong market outlook across multiple sectors.
- Development of two natural insecticides with novel modes of action
- Targeting $31 billion global markets including crop protection and public health
- Progress in regulatory milestones and pilot-scale production
- Established partnerships in US, Europe, and Israel
- Raised $2.46 million to support ongoing development and commercialization
Innovating Insecticides from Nature
Bio-Gene Technology Limited (ASX, BGT) presented a comprehensive update at its 2025 Annual General Meeting, showcasing significant strides in the development of two insecticides derived from natural sources, Flavocide and Qcide. Both products leverage unique compounds extracted from a specific eucalypt species, offering novel modes of action designed to combat major pest resistance issues that challenge conventional insecticides.
These innovations are positioned to meet growing global demand for safer, environmentally friendly pest control solutions. Flavocide, synthesized via a proprietary process, and Qcide, a natural oil from eucalypt leaves harvested in Queensland, represent Bio-Gene’s commitment to sustainable agriculture and public health.
Tapping into Large and Diverse Markets
Bio-Gene targets a broad spectrum of markets valued at approximately $31 billion, spanning crop protection, grain storage, public health vector control, consumer applications, and animal health. This diversified approach not only mitigates risk but also capitalizes on multiple growth drivers, including regulatory pressures against traditional chemicals and rising consumer preference for eco-friendly products.
Notably, the mosquito control segment alone is projected to grow by 38% through 2026, underscoring the relevance of Flavocide in combating diseases like malaria, Zika, and dengue. Meanwhile, Qcide’s application in grain storage and crop protection addresses persistent challenges such as pest resistance and import restrictions in key agricultural markets.
Progressing Through Regulatory and Commercial Milestones
The company has made tangible progress on regulatory fronts, with pilot-scale production completed for Flavocide at Rallis India Ltd and the 14th harvest of Qcide leaves finalized in Queensland. Feedback from the Australian Pesticides and Veterinary Medicines Authority (APVMA) has guided development plans, with dossier submissions for active constituents and formulated products underway.
Bio-Gene’s strategic partnerships with Clarke Mosquito (US), Evergreen Garden Care (Europe, UK, Australia, New Zealand), and STK (Israel) provide critical commercial validation and distribution channels. These collaborations are expected to accelerate market entry and expand product reach across multiple geographies.
Capital and Intellectual Property Strength
Supporting its development pipeline, Bio-Gene successfully raised $2.46 million through a placement and share purchase plan, reinforcing its financial position to advance regulatory approvals and scale manufacturing. The company also secured new patents and filed additional applications covering pest control, synergistic combinations, and ovicidal activity, strengthening its intellectual property portfolio across key territories including Australia, the US, Europe, Latin America, Asia, and Africa.
Looking ahead, Bio-Gene’s focused strategy emphasizes efficient capital use, speed to market, and building a robust commercial profile through partnerships and product development. The company anticipates multiple catalysts over the next 18 months, including regulatory dossier submissions, scale-up milestones, and potential new licensing agreements.
Bottom Line?
Bio-Gene’s natural insecticides are poised to disrupt multiple markets, but regulatory approvals and partner expansions will be critical to unlocking their full value.
Questions in the middle?
- When will Flavocide and Qcide receive final regulatory approvals in major markets?
- How will Bio-Gene scale production to meet anticipated global demand?
- What new partnerships or licensing deals might emerge to accelerate commercialisation?